File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/21645515.2018.1514227
- Scopus: eid_2-s2.0-85053886372
- PMID: 30261146
- WOS: WOS:000467953800020
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine
Title | Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine |
---|---|
Authors | |
Keywords | 9vHPV vaccine Clinical trial Geometric mean titers (GMTs) Human papillomavirus Recurrent respiratory papillomatosis |
Issue Date | 2019 |
Publisher | Taylor & Francis Inc. The Journal's web site is located at http://www.tandfonline.com/khvi |
Citation | Human Vaccines & Immunotherapeutics, 2019, v. 15 n. 1, p. 141-145 How to Cite? |
Abstract | Background: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) vaccine in a pivotal efficacy study (V503-001, NCT 00543543).
Methods: A total of 21 mother-infant pairs had evaluable HPV 6/11 results available for analysis. HPV6/11 antibodies were assessed using competitive Luminex immunoassay. The distribution of the ratios of infant to mother anti-HPV antibodies (i.e., infant-anti-HPV/mother- anti-HPV) was summarized.
Results: All mothers and infants were seropositive to HPV 6 and HPV 11. Anti-HPV 6/11 geometric mean titers (GMTs) in peripartum maternal blood and in cord blood of infant born to study participants were highly correlated. A 100% of infants born to seropositive mothers were also seropositive. The GMT ratios of peripartum maternal blood vs. those in cord blood were HPV 6: 1.23 [0.43, 3.49] and HPV 11: 1.29 [0.54, 3.07] in the 9vHPV vaccine group and HPV 6: 1.33 [0.41, 4.29] and HPV 11: 1.19 [0.45, 3.13] in the qHPV vaccine group, respectively.
Conclusions: These results indicate that antibodies induced by the 9vHPV vaccine cross the placenta, which could potentially be beneficial against HPV6/11 infection and related disease such as recurrent respiratory papillomatosis. |
Persistent Identifier | http://hdl.handle.net/10722/269483 |
ISSN | 2021 Impact Factor: 4.526 2020 SCImago Journal Rankings: 1.043 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Guevara, AM | - |
dc.contributor.author | Suarez, E | - |
dc.contributor.author | Victoria, A | - |
dc.contributor.author | Ngan, HYS | - |
dc.contributor.author | Hirschberg, AL | - |
dc.contributor.author | Fedrizzi, E | - |
dc.contributor.author | Bautista, O | - |
dc.contributor.author | Shields, C | - |
dc.contributor.author | Joshi, A | - |
dc.contributor.author | Luxembourg, A | - |
dc.date.accessioned | 2019-04-24T08:08:38Z | - |
dc.date.available | 2019-04-24T08:08:38Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Human Vaccines & Immunotherapeutics, 2019, v. 15 n. 1, p. 141-145 | - |
dc.identifier.issn | 2164-5515 | - |
dc.identifier.uri | http://hdl.handle.net/10722/269483 | - |
dc.description.abstract | Background: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) vaccine in a pivotal efficacy study (V503-001, NCT 00543543). Methods: A total of 21 mother-infant pairs had evaluable HPV 6/11 results available for analysis. HPV6/11 antibodies were assessed using competitive Luminex immunoassay. The distribution of the ratios of infant to mother anti-HPV antibodies (i.e., infant-anti-HPV/mother- anti-HPV) was summarized. Results: All mothers and infants were seropositive to HPV 6 and HPV 11. Anti-HPV 6/11 geometric mean titers (GMTs) in peripartum maternal blood and in cord blood of infant born to study participants were highly correlated. A 100% of infants born to seropositive mothers were also seropositive. The GMT ratios of peripartum maternal blood vs. those in cord blood were HPV 6: 1.23 [0.43, 3.49] and HPV 11: 1.29 [0.54, 3.07] in the 9vHPV vaccine group and HPV 6: 1.33 [0.41, 4.29] and HPV 11: 1.19 [0.45, 3.13] in the qHPV vaccine group, respectively. Conclusions: These results indicate that antibodies induced by the 9vHPV vaccine cross the placenta, which could potentially be beneficial against HPV6/11 infection and related disease such as recurrent respiratory papillomatosis. | - |
dc.language | eng | - |
dc.publisher | Taylor & Francis Inc. The Journal's web site is located at http://www.tandfonline.com/khvi | - |
dc.relation.ispartof | Human Vaccines & Immunotherapeutics | - |
dc.subject | 9vHPV vaccine | - |
dc.subject | Clinical trial | - |
dc.subject | Geometric mean titers (GMTs) | - |
dc.subject | Human papillomavirus | - |
dc.subject | Recurrent respiratory papillomatosis | - |
dc.title | Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine | - |
dc.type | Article | - |
dc.identifier.email | Ngan, HYS: hysngan@hkucc.hku.hk | - |
dc.identifier.authority | Ngan, HYS=rp00346 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1080/21645515.2018.1514227 | - |
dc.identifier.pmid | 30261146 | - |
dc.identifier.pmcid | PMC6363163 | - |
dc.identifier.scopus | eid_2-s2.0-85053886372 | - |
dc.identifier.hkuros | 297622 | - |
dc.identifier.volume | 15 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 141 | - |
dc.identifier.epage | 145 | - |
dc.identifier.isi | WOS:000467953800020 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 2164-5515 | - |